Stockreport

ImmunityBio (IBRX) Clinical Trial for Lymphona Drug Follows $505M Convertible Note Change [Yahoo! Finance]

ImmunityBio, Inc.  (IBRX) 
PDF ImmunityBio (IBRX) Clinical Trial for Lymphona Drug Follows $505M Convertible Note Change [Read more]